MX2024009650A - Sal cristalina y formas de solvato de murizatoclax (amg 397). - Google Patents
Sal cristalina y formas de solvato de murizatoclax (amg 397).Info
- Publication number
- MX2024009650A MX2024009650A MX2024009650A MX2024009650A MX2024009650A MX 2024009650 A MX2024009650 A MX 2024009650A MX 2024009650 A MX2024009650 A MX 2024009650A MX 2024009650 A MX2024009650 A MX 2024009650A MX 2024009650 A MX2024009650 A MX 2024009650A
- Authority
- MX
- Mexico
- Prior art keywords
- solvate forms
- amg
- salt
- murizatoclax
- crystalline salt
- Prior art date
Links
- 150000003839 salts Chemical group 0.000 title abstract 5
- 239000012453 solvate Chemical group 0.000 title abstract 5
- BJTFTQIBRVBSBH-VCQPVEJUSA-N CO[C@]1(CN2CCN3CCCC[C@@H]3C2)\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 Chemical compound CO[C@]1(CN2CCN3CCCC[C@@H]3C2)\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 BJTFTQIBRVBSBH-VCQPVEJUSA-N 0.000 title abstract 3
- BJTFTQIBRVBSBH-MUHQWPPJSA-N murizatoclax Chemical compound [H][C@]12CC[C@@H]1CN1C[C@@]3(CCCC4=CC(Cl)=CC=C34)COC3=C1C=C(C=C3)C(=O)NS(=O)(=O)[C@@H](C)[C@H](C)C\C=C\[C@@]2(CN1CCN2CCCC[C@]2([H])C1)OC BJTFTQIBRVBSBH-MUHQWPPJSA-N 0.000 title 1
- 229940071537 murizatoclax Drugs 0.000 title 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 abstract 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306781P | 2022-02-04 | 2022-02-04 | |
| PCT/US2023/012252 WO2023150250A1 (en) | 2022-02-04 | 2023-02-03 | Crystalline salt and solvate forms of murizatoclax (amg 397) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009650A true MX2024009650A (es) | 2024-08-14 |
Family
ID=86054183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009650A MX2024009650A (es) | 2022-02-04 | 2023-02-03 | Sal cristalina y formas de solvato de murizatoclax (amg 397). |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250122224A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4472985A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025505142A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023215171A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3248348A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024009650A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023150250A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119255998A (zh) | 2022-05-04 | 2025-01-03 | 吉利德科学公司 | 特定mcl-1抑制剂的盐和多晶型物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| JP6453507B2 (ja) * | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Mcl−1タンパク質を阻害する化合物 |
| JP7873057B2 (ja) * | 2020-03-31 | 2026-06-11 | アムジエン・インコーポレーテツド | Mcl-1化合物のメチル化 |
-
2023
- 2023-02-03 MX MX2024009650A patent/MX2024009650A/es unknown
- 2023-02-03 WO PCT/US2023/012252 patent/WO2023150250A1/en not_active Ceased
- 2023-02-03 EP EP23718377.7A patent/EP4472985A1/en active Pending
- 2023-02-03 CA CA3248348A patent/CA3248348A1/en active Pending
- 2023-02-03 JP JP2024545809A patent/JP2025505142A/ja active Pending
- 2023-02-03 US US18/730,353 patent/US20250122224A1/en active Pending
- 2023-02-03 AU AU2023215171A patent/AU2023215171A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250122224A1 (en) | 2025-04-17 |
| JP2025505142A (ja) | 2025-02-21 |
| CA3248348A1 (en) | 2023-08-10 |
| AU2023215171A1 (en) | 2024-07-04 |
| EP4472985A1 (en) | 2024-12-11 |
| WO2023150250A1 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000216A (es) | Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona | |
| PE20221762A1 (es) | Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos | |
| EP4647129A3 (en) | PROCESS FOR PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A!PYRROLO[2,3-E!PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID FORMS THEREIN | |
| UY27380A1 (es) | Compuestos de heteroarilo bicíclicos fusionados sustituidos con heteroarilo como ligandos del receptor gabaa | |
| HUT74679A (en) | K-252a indolocarbazole alkaloid derivatives which enhance neurotrophin-induced activity | |
| TW200738660A (en) | Piperidinyl derivatives as modulators of chemokine receptor activity | |
| ES2178668T4 (es) | Naftilamidas como agentes del sistema nervioso central. | |
| EE9900079A (et) | Meetod 21-atsüüloksüpregna-1,4-dieen-11ß,16a,17a-triool-3,20-diooni derivaatide 16,17-atsetaalderivaatide R-epimeerseks rikastamiseks | |
| ES2078405T3 (es) | Procedimiento para la purificacion de insulinas por cromatografia. | |
| MX2024009448A (es) | Formas cristalinas de un inhibidor de mcl-1. | |
| ES2054723T3 (es) | Tetrahidropiridinoximas, procedimiento para su preparacion y uso de las mismas como agentes colinergicos. | |
| AU2016211630A1 (en) | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | |
| BRPI0509514A (pt) | métodos para a preparação de (3r,3as,6ar)-hexaidro-furo[2,3-b]-furan-3-ol | |
| IL272652B (en) | A pentacyclic compound, the pharmaceutical compounds that make it up and their use for the treatment of Alzheimer's disease | |
| UY25501A1 (es) | Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo [4.3.0]nonano | |
| Baxter et al. | Some studies on the convulsant action of folic acid | |
| MX2025012360A (es) | Derivados de pirrolopiridina como moduladores alostericos positivos del receptor muscarinico de acetilcolina m4 | |
| Cabral-Miranda et al. | Astrocytic proteostasis in the tale of aging and neurodegeneration | |
| Zhang et al. | Inhibition of astroglial hemichannels ameliorates infrasonic noise induced short-term learning and memory impairment | |
| Norambuena et al. | Language, analogical reasoning, and working memory skills in emergent literacy period: Typical and DLD trajectories via Cluster Analyses | |
| MX2025012362A (es) | Derivados de 1,6-naftiridina como moduladores alostericos positivos del receptor muscarinico de acetilcolina m4, utiles para el tratamiento de trastornos neurologicos y psiquiatricos | |
| CY1125134T1 (el) | Ενωσεις 1,2,3',5'-τετραϋδρο-2'h-σπειρο[ινδολο-3,1'-πυρρολο[3,4-c]πυρρολο]-2,3'-διονης ως θεραπευτικοι παραγοντες που ενεργοποιουν τρ53 | |
| MX2024012192A (es) | Formas de sal y solvatos de antagonistas de mci-1 | |
| Perovic et al. | The effect of age on language in adults with intellectual disabilities: A comparison of passives in Down syndrome and Williams syndrome | |
| Ross et al. | A simple eyelid conditioning masking task and its effect on differential conditioning |